Beginning in 2023, the medical marijuana industry in Maryland, United States, will be regulated by the state's alcohol and tobacco commission.
The Marijuana Medical Commission of Maryland (MMCC) has been overseeing the state's medical marijuana industry since sales began in December 2017.
During the midterm elections in November, the situation changed as Maryland voters decided to legalize the sale of marijuana for adult use.
According to a press release from MMCC, the regulation of medical marijuana will transition from the Medical Marijuana Commission to the Alcohol and Tobacco Commission in 2023, as mandated by a law passed by voters.
According to an announcement, Chairperson Tiffany Randolph will step down on December 31st.
In the past five years, commission members and staff have established Maryland as a model for medical marijuana programs and have helped the state prepare for the transition to an expanded medical and adult-use market," said Randolph in a statement.
According to a press release, Dr. C. Obi Onyewu, current Vice-Chair of MMCC, will serve as acting Chair as Maryland launches a recreational marijuana market.
Starting from July 1, 2023, it will be legal for adults aged 21 and above to consume and possess up to 1.5 ounces of marijuana.
The true retail market may not begin until 2024 or 2025.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
